High-throughput sequencing technology is widely used in tumor genetic testing. On the one hand, gene sequencing can identify the mutated genes of cancer and thus rapidly determine the targeted drugs; on the other hand, the sample type can be the patient's blood or even saliva, eliminating the need for traditional pathological sections and reducing the damage to the patient's organism during the diagnostic process.

High-throughput sequencing, also known as next-generation sequencing (NGS), is a technique that sequences hundreds of thousands to millions of nucleic acid molecules at a time, as opposed to traditional first-generation sequencing (Sanger sequencing). This technology prepares a sequencing library by randomly fragmenting and splicing DNA, and finally obtains sequence information by performing extension reactions on tens of thousands of clones in the library and detecting the corresponding signals.

NGS is the process of randomly fragmenting and splicing DNA to prepare a sequencing library. By performing extension reactions on the tens of thousands of clones in the library, the corresponding signals are detected and sequence information is finally obtained.

The morphological and structural characteristics of the tissue of FFPE samples are observed experimentally or analyzed by immunohistochemistry with antibodies. However, with the development of technology, more and more people tend to choose to apply the latest techniques at the molecular level for in-depth data mining.